Turcan et al. (2012) showed that IDH1 mutation modulates the differentiation state by increasing the nestin levels in normal human astrocytes (NHAs). Moreover, these IDH1 mutant cells produce higher levels of 2-HG, which is normally observed in low-grade brain tumors. According to the literature, the IDH mutation in cancer patients is associated with better prognostic and survival rate, suggesting that IDH could be a promising target to reduce the aggressiveness of GB by modulating the astrocytes activity (Turcan et al., 2012). The gene discussed is IDH2; the disease is brain neoplasm.